Cevimeline (cas 107233-08-9), also known as SNI-2011, is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. Cevimeline stimulates the peripheral muscarinic acetylcholine receptors of salivary glands and increases the concentration of Ca+2 in parotic acini and duct cells of rats. It is used in the treatment of dry mouth associated with sjogren/'s syndrome.
1. Nihon Yakurigaku Zasshi. 2002 Oct;120(4):253-8.
[Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its
pharmacological profiles and clinical potential in xerostomia].
(1)Scientific Affairs Department Pharmaceuticals Group, Nippon Kayaku Co. Ltd.,
Tokyo Fujimi Bldg., 11-2, Fujimi 1-Chome, Chiyoda-ku, Tokyo 102-8172, Japan.
Cevimeline hydrochloride hydrate is a muscarinic receptor agonist with a chemical
structure of a quinuclidine. Intraduodenal administration of cevimeline
hydrochloride hydrate dose-dependently increased salivary secretion in normal
mice and rats, two strains of autoimmune disease mice, and X-irradiated rats. The
clinical efficacy of the cevimeline hydrochlide hydrate at 30 mg t.i.d. during 4
weeks has been demonstrated in double blind comparative study with placebo. In
addition, its treatments in 52 weeks have increased salivary flow and improved
subjective and objective symptoms of patients with xerostomia in Sjögren/'s
2. Adv Exp Med Biol. 2002;506(Pt B):1107-16.
Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren/'s
(1)Allergy and Rheumatology Clinic, Scripps Memorial Hospital and Research
Foundation, La Jolla, California, USA.